谷氨酸系统相关药物在难治性强迫症治疗中的应用进展  

Application Progress of Glutamate System Related Drugs in Treatment of Refractory Obsessive-Compulsive Disorder

作　　者：战玉华[1] 王旭梅[1] ZHAN Yuhua;WANG Xumei(Department of Psychiatry,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院心理门诊

出　　处：《医学综述》2019年第14期2872-2878,共7页Medical Recapitulate

基　　金：辽宁省自然科学基金(2015020516)

摘　　要：目前,选择性5-羟色胺再摄取抑制剂(SSRIs)是治疗强迫症的主要药物,但这些药物的疗效有限。经过两种或两种以上SSRIs足量足疗程治疗仍无效果的强迫症属于难治性强迫症,人们正在不断探索治疗难治性强迫症更有效的方法。谷氨酸系统失调与强迫症发病有关,参与强迫症的病理生理过程,且很多谷氨酸系统的调节药物被用于难治性强迫症的治疗,如N-甲基-D-天冬氨酸受体(NMDAR)拮抗剂和NMDAR激动剂等,其中一些药物也显示出显著的效果,这为难治性强迫症提供了新的治疗选择。Currently,selective serotonin reuptake inhibitors(SSRIs) are the main treatment drugs for obsessive-compulsive disorder,but these drugs have limited efficacy.Refractory obsessive-compulsive disorder is an obsessive-compulsive disorder that has been treated with enough quantiy/courses of two or more SSRIs without effect.Therefore,people are constantly exploring more effective treatments for refractory obsessive-compulsive disorder.In recent years,there is increasing evidence that glutamate system disorders are associated with the pathogenesis of obsessive-compulsive disorder and are involved in the pathophysiological processes of obsessive-compulsive disorder.Moreover,many glutamate-related regulatory drugs have been used to treat refractory obsessive-compulsive disorder,such as N-methyl- D -aspartate receptor(NMDAR) antagonists and NMDAR agonists,some of which have shown significant effects,providing a new treatment option for refractory obsessive-compulsive disorder.

关 键 词：强迫症 难治性强迫症 谷氨酸 选择性5-羟色胺再摄取抑制剂 N-甲基-D-天冬氨酸受体拮抗剂 

分 类 号：R749.053[医药卫生—神经病学与精神病学]